Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY
| Status: | Archived |
|---|---|
| Conditions: | Cancer, Blood Cancer, Lymphoma, Hematology, Leukemia |
| Therapuetic Areas: | Hematology, Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | May 2009 |
| End Date: | January 2020 |
Trial of Allogeneic BMT for Hematologic Malignancies Using HLA-matched Related or Unrelated Donors With Fludarabine and IV Busulfan as Pre-transplant Conditioning Followed by Post-transplant Immunosuppression With High-dose Cyclophosphamide
The purpose of this research is to find the most effective and least toxic way to prevent
GVHD after BMT.
A person who has cancer of the blood or lymph glands can be treated by bone marrow
transplantation (BMT). BMT has developed over several decades of research on both animal
and human subjects as an effective treatment of various malignant and nonmalignant
hematologic diseases. Many hematologic malignancies can be successfully treated with a
combination of high-dose chemotherapy or chemo-radiotherapy and transplantation of
allogeneic bone marrow or peripheral blood stem cells (alloBMT)
However, a possible side effect of BMT is graft versus host disease (GVHD). GVHD occurs
when cells of the donor's immune system, which are present in the bone marrow, attack the
BMT recipient's normal tissue. Prevention of GVHD is important for the success of the bone
marrow transplant. This research is being done to find the most effective and least toxic
way to prevent GVHD after BMT
We found this trial at
3
sites
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins The name Johns Hopkins has become synonymous...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials